$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
Oncology
Oncology
Oncology_Medical Halo Global Medical Oncology News_Oncology Drug Therapy News
患者服用奥希替尼的注意事项?
2025-10-19 11:44:20
Check Details
克唑替尼的服药说明
2025-10-19 11:44:20
Check Details
克唑替尼对于ROS1重排NSCLC治疗非常有效
2025-10-19 11:44:20
Check Details
克唑替尼如何服用?
2025-10-19 11:44:20
Check Details
奥希替尼治疗 T790M突变NSCLC优于化疗
2025-10-19 11:44:20
Check Details
第三代表皮生长因子受体酪氨酸激酶抑制剂研究数据
2025-10-19 11:44:20
Check Details
患者服用克唑替尼产生耐药怎么办?
2025-10-19 11:44:20
Check Details
克唑替尼治疗ROS1重排的肺癌患者效果较好
2025-10-19 11:44:20
Check Details
阿法替尼获批治疗EGFR突变阳性的NSCLC患者
2025-10-19 11:44:20
Check Details
患者吞咽困难,如何服用奥希替尼?
2025-10-19 11:44:20
Check Details
奥希替尼治疗肺癌脑转移的效果
2025-10-19 11:44:20
Check Details
奥希替尼成为国际性首个治疗T790M突变的NSCLC靶向药
2025-10-19 11:44:20
Check Details
1
2
...
2970
2971
2972
2973
2974
2975
2976
...
4153
4154
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Elacestrant: Precision Therapy for ESR1-Mutant Resistant HR+/HER2- Advanced Breast Cancer
2
Selpercatinib Complete Medication Guide: Indications, Dosage and Safety Information for RET Inhibitor
3
Complete Guide to Dosage and Dose Adjustment of Entrectinib
4
Comprehensive Analysis of Bleeding Risk with Tepotinib in MET-Mutated Non-Small Cell Lung Cancer
5
Lomustine vs Temozolomide: Comprehensive Comparison of Efficacy and Safety in Glioma Treatment
6
Tepotinib and Osimertinib: Current Status and Clinical Positioning of Combination Therapy in Non-Small Cell Lung Cancer
7
Tumor Shrinkage Effect and Core Therapeutic Value of Pazopanib
8
Tabrecta (Capmatinib): A Targeted Therapy for METex14-Mutated NSCLC
9
Pazopanib Shows Promise as Second-Line Therapy for Aggressive Skin Cancer
10
Managing Immunotherapy-Related Adverse Events of Tarlatamab-Imdelltra: A Guide to Dual-Specific T Cell Engager Safety
11
Almonertinib Safety Guide: Managing Adverse Reactions in NSCLC Treatment with a 3rd-Gen EGFR TKI
12
Pimitespib Storage Guidelines: Temperature, Humidity & Light Control for Home Use